Tue. 2 Apr 2024, 1:43am ET
Benzinga
News
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 —
— First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibitor —